Abstract: Disclosed is a type of borosilicate glass, the composition of which, based on oxides, contains the following components by weight percentage (wt %): 2.0 wt %-5.0 wt % of TiO2, 0.25 wt %-2.5 wt % of CeO2 and 0.25 wt %-3.0 wt % of Y2O3, and does not contain any iron compound, such as ferric oxide. The glass has better UV resistance and alkaline resistance properties, and a better light transmission rate, and is particularly suitable for use in the field of pharmaceutical packaging materials.
Abstract: The present invention relates to an oral complex preparation comprising: a capsule containing a fat-soluble first drug; and a solid preparation containing a second drug, the solid preparation being embedded into the capsule and including an oil-proof material coating layer on the surface thereof The oral complex preparation of the present invention prepared by embedding the solid preparation including the oil-proof material coating layer on the surface thereof and containing the second drug into the capsule containing the fat-soluble first drug enables two types of drug ingredients to be simultaneously administered.
Type:
Grant
Filed:
February 3, 2017
Date of Patent:
June 15, 2021
Assignees:
Korea United Pharm, Inc., United Science R&D Center
Inventors:
Yun Woong Choi, Dae Chul Ha, In Ho Kwon, Byung Jin Kim, Hee Yong Song, Min-Seok Kwon, Byung Gu Min, Sang Min Cho, Jae Sang Jang
Abstract: The present invention relates to a pharmaceutical composition containing, as an active ingredient, niclosamide or pharmaceutically acceptable salts thereof, for treating or preventing disease related to Axin-GSK3 interaction, such as familial adenomatosis polyposis (FAP). According to the present invention, familial adenomatosis polyposis (FAP) which causes pain due to lack of specific treatment methods, can be effectively treated using niclosamide, which is a safe drug approved by the FDA.
Type:
Grant
Filed:
January 9, 2018
Date of Patent:
June 15, 2021
Assignee:
BAOBAB PHARM CO., LTD.
Inventors:
Jong In Yook, Hyun Sil Kim, Nam Hee Kim, Kyoung Tai No, Ji Won Choi, Tae Il Kim, Sung Yong Ahn
Abstract: Provided are a novel [1,2,4]triazolo[4,3-a]quinoxaline derivative, a method for preparing the same, and a pharmaceutical composition for preventing or treating bromodomain extra-terminal (BET) protein-related diseases including cancer and autoimmune diseases, containing the same as an active ingredient.
Type:
Grant
Filed:
January 25, 2018
Date of Patent:
June 8, 2021
Assignees:
Dong Wha Pharm. Co., Ltd., Korea Research Institute of Chemical Technology
Inventors:
Kwangho Lee, Gildon Choi, Imran Ali, Joo Yun Lee, Jin Soo Lee, Whui Jung Park, Yong Tae Kim, Seung Hwan Kim, Jung Hwan Kim, Jae-Kyung Lim
Abstract: The present invention provides a preparation method for a natural product Trabectedin. Specifically, the present invention provides a preparation method for Et-743. In the method, tyrosine is used as an initial substrate, and after 26 steps of reaction, the Et-743 is synthesized. Raw materials and agents used in the synthetic route can all easily be obtained, reaction conditions are relatively mild, and preparation in large scale can be implemented.
Abstract: A crystalline form of an alkyl benzene sulfonyl urea compound that is useful as an oral antidiabetics is disclosed. Specifically, the compound is a hydrochloride salt of N-(3-(2-(4-(4-methylpiperazin-1-yl)phenylamino)thieno[3,2-d]pyrimidin-4-yloxy)phenyl)acrylamide of the following formula I.
Type:
Grant
Filed:
December 30, 2016
Date of Patent:
May 18, 2021
Assignee:
HANMI PHARM. CO., LTD.
Inventors:
Jong Ouk Baek, Ji Young Jeon, Hee Sook Oh, Hee Cheol Kim, Sun Young Jang, Tae Hee Ha
Abstract: A sustained release preparation of a human growth hormone conjugate is disclosed. The sustained release preparation contains a sustained release human growth hormone (hGH) conjugate resulting from conjugation between an immunoglobulin Fc region and a human growth hormone (hGH) as an active peptide; a buffer solution; a nonionic surfactant; and a sugar alcohol. A freeze dried preparation and a liquid preparation including the sustained release human growth hormone conjugate, a production method for the freeze dried preparation, a method of reconstituting the freeze dried preparation, and a kit containing the freeze dried preparation and a reconstituting solution are also disclosed.
Type:
Application
Filed:
December 28, 2020
Publication date:
May 13, 2021
Applicant:
HANMI PHARM. CO., LTD.
Inventors:
Hwa Peoung RIM, Hyun Uk KIM, Ho Taek IM, Sang Yun KIM, Hyung Kyu LIM, Sung Min BAE, Se Chang KWON
Abstract: The present invention relates to a composite preparation with various dosage forms comprising mosapride and rabeprazole. The composite preparation prepared according to the present invention allows rapid release of a drug without deteriorating its release by an interaction between mosapride and rabeprazole, thus exhibiting an improved drug release rate and bioavailability, while having excellent product stability and being capable of significantly lowering the amount of the excipient. Accordingly, the composite preparation of the present invention can improve patients' drug compliance due to the size of its dosage form.
Type:
Grant
Filed:
June 27, 2016
Date of Patent:
May 11, 2021
Assignee:
KOREA UNITED PHARM. INC.
Inventors:
Youn Woong Choi, Hee Yong Song, Dae-Chul Ha, Byung Jin Kim
Abstract: The present invention relates to a sustained type human growth hormone conjugate preparation comprising: a sustained type human growth hormone (hGH) conjugate resulting from conjugation between the immunoglobulin Fc region and a human growth hormone (hGH) constituting a bioactive peptide; a buffer solution; a nonionic surfactant; and a sugar alcohol. More specifically, the present invention relates to a sustained type human growth hormone conjugate freeze dried preparation and liquid preparation, to a production method for the freeze dried preparation, to a method of reconstituting the freeze dried preparation, and to a kit comprising the freeze dried preparation and a reconstituting solution.
Type:
Grant
Filed:
September 26, 2014
Date of Patent:
April 27, 2021
Assignee:
HANMI PHARM. CO., LTD.
Inventors:
Hwa Peoung Rim, Hyun Uk Kim, Ho Taek Im, Sang Yun Kim, Hyung Kyu Lim, Sung Min Bae, Se Chang Kwon
Abstract: The present invention relates to a liquid formulation of long-acting insulin conjugate, comprising a pharmaceutically effective amount of a long-acting insulin conjugate, wherein a physiologically active peptide, which is an insulin, is linked to an immunoglobulin Fc region; and an albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, a non-ionic surfactant, and an isotonic agent, and a method for preparing the formulation. For preventing microbial contamination in multiple uses, a preservative can be added to the formulation. The liquid formulation of the present invention does not comprise a human serum albumin and potentially hazardous factors to body, and thus it has excellent storage stability for insulin conjugate without a risk of viral infection.
Type:
Grant
Filed:
July 25, 2013
Date of Patent:
April 27, 2021
Assignee:
HANMI PHARM. CO., LTD.
Inventors:
Hyung Kyu Lim, Hyun Uk Kim, Sung Hee Hong, Min Young Kim, Sung Min Bae, Se Chang Kwon
Abstract: Fully human anti-PD-L1 antibodies and their corresponding applications. Fully human antibodies capable of specifically binding to human PD-L1 were obtained by employing a yeast display library-based screening technique and also by affinity maturation to further improve their affinity for PD-L1. The fully human anti-PD-L1 antibodies show good specificity, affinity and stability. They are capable of enhancing T cell activity by binding to activated T cells, while significantly inhibiting tumor growth, and can be used in the diagnosis and treatment of PD-L1-related cancers and other associated diseases.
Type:
Application
Filed:
April 18, 2018
Publication date:
April 22, 2021
Applicant:
R-PHARM OVERSEAS, INC.
Inventors:
Yan LAVROVSKY, Ting XU, Sergei BARBASHOV, Alexey REPIK, Mikhail SAMSONOV, Vasily IGNATIEV, Shorena ARCHUADZE
Abstract: The present invention relates to a modified IgG4 Fc fragment useful as a drug carrier. When the modified IgG4 Fc fragment of the present invention is combined with an arbitrary drug, the resulting drug conjugate can minimize the effector functions of the IgG4 Fc and the chain exchange with in vivo IgG while maintaining in vivo activity and improving in vivo duration of the drug conjugate.
Type:
Grant
Filed:
May 29, 2014
Date of Patent:
April 13, 2021
Assignee:
HANMI PHARM. CO., LTD.
Inventors:
Sung Youb Jung, Yong Ho Huh, Sung Hee Park, Jong Soo Lee, In Young Choi
Abstract: A composition for preventing the hair loss or promoting the hair growth includes Wnt protein-derived peptides and polydeoxyribonucleotides as an active ingredient, and increases the secretion of ?-catenin. By the cell activation and activation of signal transduction pathway for promoting the hair growth signaling system, the growth of hair constituent cells, such as keratinocytes, fibroblasts and dermal papilla cells, is increased to prevent the hair loss or promote the hair growth. Wnt protein-derived peptides and polydeoxyribonucleotides are used as a cosmetic composition, a pharmaceutical composition or a health food composition for preventing the hair loss or promoting the hair growth.
Type:
Grant
Filed:
November 6, 2019
Date of Patent:
April 13, 2021
Assignee:
BR PHARM CO., LTD.
Inventors:
Seok Soon Kim, Boon Saeng Park, Il Gi Kim
Abstract: The present invention relates to a composition comprising 2,4,6-trihydroxyacetophenone (THA) as an effective ingredient for prevention or treatment of prostate cancer. THA in the present invention is a main ingredient of Curcuma comosa. The composition of the present invention effectively inhibits the growth of prostate cancer by regulating in particular the activity of polo-like kinase 1 (PLK1) and thus is expected to find useful applications in use in the prevention, alleviation, and treatment of prostate cancer in future.
Abstract: Disclosed is a test strip for detecting microalbumin in urine, and more particularly a test strip for detecting microalbumin in urine that contains a synthetic albumin indicator, a buffer solution, a surfactant and a polymer (sensitizer) and thus exhibits high sensitivity. The albumin detection test strip has accuracy sufficient to enable clear observation of color change from colorless to blue through the albumin indicator, and improves the detection limit (increases sensitivity) to thereby enable detection of microalbuminuria at a concentration of 20 mg/L or less. The albumin test detection strip contains a surfactant and a polymer in addition to a synthetic albumin indicator, thereby incorporating separate first and second processes into a single process and having effects of reducing costs, improving processing convenience, and increasing solubility and miscibility.
Type:
Application
Filed:
September 8, 2020
Publication date:
April 1, 2021
Applicant:
CHUNGDO PHARM. CO., LTD
Inventors:
Sung Jin KIM, Abeje Abebayehu SILTE, Hyun Ah KIM
Abstract: Disclosed is a convenient single-agent-type self-oxidative hair dye that has the same effect as a conventional hair dye, which is used by mixing a hair dye as a first agent with an oxidizing agent as a second agent, by incorporating a dye having a benzenetriol structure as a self-oxidative dye that strongly absorbs oxygen in the air to cause oxidation in order to solve the problem of defective or insufficient dyeing occurring due to shortage of oxygen required for polymerization when dyeing hair using only the hair dye as the first agent without an oxidizing agent.
Type:
Grant
Filed:
November 8, 2019
Date of Patent:
March 23, 2021
Assignee:
Dong Sung Pharm. Co., Ltd.
Inventors:
Bonglim Jo, Hyejin Moon, Juhee Hong, Yuna Sim
Abstract: Disclosed is a pharmaceutical formulation containing esomeprazole or a pharmaceutically acceptable salt thereof. The pharmaceutical formulation, based on considerably improved pH-dependent drug release characteristics, starts to release the esomeprazole or a pharmaceutically acceptable salt thereof at a target delay time after oral administration, continues the release for a predetermined time, and finishes the release after a predetermined time, thereby providing excellent patient convenience and excellent therapeutic effects, as compared to conventional other formulations.
Type:
Grant
Filed:
July 24, 2017
Date of Patent:
March 16, 2021
Assignee:
HANMI PHARM. CO., LTD.
Inventors:
Taek Kwan Kwon, Kwang Young Lee, Ho Taek Im, Yong Il Kim, Jae Hyun Park, Jong Soo Woo
Abstract: A modified IgG4 Fc fragment useful as a drug carrier is disclosed. When coupled to a drug, the resulting drug-IgG4 Fc conjugate can minimize the effector functions of the IgG4 Fc and the chain exchange with in vivo IgG while maintaining in vivo activity and improving in vivo duration of the drug conjugate.
Type:
Application
Filed:
November 13, 2020
Publication date:
March 4, 2021
Applicant:
HANMI PHARM. CO., LTD
Inventors:
Sung Youb JUNG, Yong Ho Huh, Sung Hee Park, Jong Soo Lee, In Young Choi
Abstract: The present invention is directed to an intelligent portable health monitoring apparatus, which is for the purpose of health surveillance. Specifically, the invention of an intelligent portable health monitoring apparatus comprises: a mainboard, and more than one set of photoelectric sensors connecting with the mainboard electronically, the more than one set of photoelectric sensors are able to adjust positions to cover the detected site properly by moving either the photoelectric transmitter or the photoelectric receiver, in order to acquire user's pulse and blood data. With the present invention of an intelligent portable health monitoring apparatus, it solves the problem of errors advantageously, which are induced by the differences of individual users during the noninvasive monitoring process, thus to present the users their accurate health conditions.